Transaction Overview
Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited, intends to make a Strategic Equity Partnership of 30.4% in Gate2Brain (G2B), a Barcelona-based biotechnology company.
Target Company Details
Name: GATE2BRAIN S.L.
Tax ID: B01697564
Incorporation: Company incorporated under Spanish Laws
Paid Up Share Capital: €3,855.56
Date of Incorporation: 03-07-2020
Business: Biotechnology company developing peptide-based delivery systems that transport therapeutics across the blood-brain barrier for the treatment of central nervous system diseases. The company is currently in pre-clinical stage of product development.
Transaction Structure
Equity Stake Acquired: 30.4%
Consideration Details:
- Cash infusion: Euro 0.5 million
- Equity for services: Euro 5.5 million
- Euro 1 million for development of Project
Total Contribution: Euro 7 million
Strategic Rationale and Impact
The acquisition allows Shilpa to participate in long-term value creation while contributing the manufacturing and regulatory depth required to bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories.
About G2B-002 Program
Therapy Type: Brain cancer therapy using peptide-based delivery systems
Technology: Proprietary MiniAp4 peptide shuttle technology
Indications: Targets diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM) - two of the most lethal childhood brain cancers
Regulatory Status: Granted Orphan Drug Designation (ODD) by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
Preclinical Performance: The MiniAp4 peptide shuttle has demonstrated up to 100-fold greater brain drug transport versus conventional approaches in animal models
Additional Applications: The platform has shown preclinical activity across Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma
Development Timeline: Clinical batches expected as early as next year, with first-in-human trials anticipated to commence by FY28
Market Opportunity
Glioblastoma treatment market: Estimated at approximately USD 3.01 billion in 2025 and projected to reach USD 6.48 billion by 2035, at a CAGR of 7.97%
Pediatric brain tumor market: Estimated at approximately USD 1.55 billion in 2024 and projected to reach USD 2.47 billion by 2031, at a CAGR of 6.9%
Diffuse intrinsic pontine glioma (DIPG) market: Estimated at approximately USD 603.7 million in 2025 and projected to reach USD 1.2 billion by 2035, at a CAGR of 7.1%
Management Commentary
Vishnukant Bhutada, Managing Director, Shilpa Medicare Ltd: "Gate2Brain's blood-brain-barrier technology is among the most differentiated CNS-delivery platforms we have evaluated. Becoming a strategic shareholder allows Shilpa to participate in long-term value creation while contributing the manufacturing and regulatory depth required to bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories."
Meritxell Teixidó Turà, CEO, Gate2Brain: "This partnership gives G2B-002 a clear, de-risked path to the clinic and validates our peptide-shuttle platform with a top-tier oncology partner. Aligning Shilpa's manufacturing and regulatory capabilities with our science is the right structure to deliver this program — and the next ones — to patients."
Transaction Context
This marks Shilpa's fourth strategic equity partnership of this kind, reinforcing a deliberate strategy of investing in differentiated innovation and building a portfolio of high-potential therapeutic assets.